American Journal of Case Reports and Clinical Images
Researchers have shown that it could be possible to modify the
mitochondrial genome, paving the way for new treatments for incurable
mitochondrial diseases.
Researchers from the University of
Cambridge, UK have shown it is possible to repair defective mitochondria using
gene-editing techniques in live mice. The breakthrough, which was recently
published in Nature Communications, is a step toward new treatments for
incurable mitochondrial diseases.
Faults in mitochondrial DNA can affect
how well the mitochondria operate, leading to mitochondrial diseases, serious
and often fatal conditions that affect around one in 5,000 people. Usually,
more than 60 percent of the mitochondria in a cell need to be faulty for the
disease to emerge and the more defective mitochondria a person has, the more
severe their disease will be. If the percentage of defective DNA could be
reduced, the disease could potentially be treated. A cell that contains a
mixture of healthy and faulty mitochondrial DNA is described as heteroplasmic.
If a cell contains no healthy mitochondrial DNA, it is homoplasmic.
In 2018, a team from the MRC
Mitochondrial Biology Unit at the University of Cambridge used an experimental
gene therapy treatment in mice and were able to successfully target and
eliminate the damaged mitochondria DNA in heteroplasmic cells, allowing
mitochondria with healthy DNA to take their place. Although this research was
promising, the technique would only work in cells with enough healthy
mitochondrial DNA to copy themselves and replace the faulty ones that had been
removed. Furthermore, it would not work in cells whose entire mitochondria had
faulty DNA. In their
latest research, the team used a biological tool known as a mitochondrial base
editor to edit the mitochondrial DNA of live mice. The treatment was delivered
into the bloodstream of the mouse using a modified virus, which was then taken
up by its cells. The tool looked for a unique sequence of base pairs:
combinations of the A, C, G and T molecules that make up DNA. It then changed
the DNA base (in this case, changing a C to a T), highlighting the tool could
correct certain combinations that cause the mitochondria to malfunction.
There are currently no suitable mouse
models of mitochondrial DNA diseases, so the researchers used healthy mice to
test the mitochondrial base editors. However, the research shows that it is
possible to edit mitochondrial DNA genes in a live animal.
There is clearly a long way to go before our work could lead to a treatment for mitochondrial diseases. However, it shows that there is the potential for a future treatment that removes the complexity of mitochondrial replacement therapy and would allow for defective mitochondria to be repaired in children and adults, concluded Dr Michal Minczuk, an author of the study.